PACB Pacific Biosciences of California
- 1.751
- +0.061+3.59%
Pacific Biosciences of California News
Pacific Biosciences Analyst Ratings
Pacific Biosciences Analyst Ratings
Goldman Sachs: Maintains Pacific Biosciences (PACB.US) rating, adjusted from neutral to neutral, and adjusted the target price from $7.00 to $2.50.
Goldman Sachs Maintains Neutral on Pacific Biosciences, Lowers Price Target to $2.5
Pacific Biosciences Analyst Ratings
Scotiabank: Maintaining the Pacific Biosciences (PACB.US) rating, adjusted from outperforming the market to outperforming the market rating, and the target price was adjusted from $15.00 to $8.00.
TD Cowen: Maintains Pacific Biosciences (PACB.US) rating, adjusted from buy to buy rating, and adjusted target price from $12.00 to $2.50.
Pacific Biosciences Analyst Ratings
TD Cowen Maintains Buy on Pacific Biosciences, Lowers Price Target to $2.5
Barclays: Maintaining the Pacific Biosciences (PACB.US) rating, adjusted from a shareholding wait-and-see rating to a shareholding wait-and-see rating, and the target price was adjusted from $8.00 to $3.00.
Pacific Biosciences Analyst Ratings
Canaccord Genuity Maintains Buy on Pacific Biosciences, Lowers Price Target to $10
Pacific Biosciences Analyst Ratings
UBS Trims Pacific Biosciences of California Price Target to $12 From $12.50, Maintains Buy Rating
UBS Lifts Price Target on Pacific Biosciences of California to $12.50 From $10, Keeps Buy Rating
Stephens & Co. Initiates Coverage On Pacific Biosciences With Overweight Rating, Announces Price Target of $11
Pacific Biosciences Analyst Ratings
Pacific Biosciences Analyst Ratings
UBS Upgrades Pacific Biosciences to Buy, Lowers Price Target to $10
Pacific Biosciences Analyst Ratings
Analysis
Price Target
No Data
